Abstract

According to the “gain-of-toxicity mechanism”, neuronal loss during cerebral proteinopathies is caused by accumulation of aggregation-prone conformers of misfolded cellular proteins, although it is still debated which aggregation state actually corresponds to the neurotoxic entity. Autophagy, originally described as a variant of programmed cell death, is now emerging as a crucial mechanism for cell survival in response to a variety of cell stressors, including nutrient deprivation, damage of cytoplasmic organelles, or accumulation of misfolded proteins. Impairment of autophagic flux in neurons often associates with neurodegeneration during cerebral amyloidosis, suggesting a role in clearing neurons from aggregation-prone misfolded proteins. Thus, autophagy may represent a target for innovative therapies. In this work, we show that alterations of autophagy progression occur in neurons following in vitro exposure to the amyloidogenic and neurotoxic prion protein-derived peptide PrP90-231. We report that the increase of autophagic flux represents a strategy adopted by neurons to survive the intracellular accumulation of misfolded PrP90-231. In particular, PrP90-231 internalization in A1 murine mesencephalic neurons occurs in acidic structures, showing electron microscopy hallmarks of autophagosomes and autophagolysosomes. However, these structures do not undergo resolution and accumulate in cytosol, suggesting that, in the presence of PrP90-231, autophagy is activated but its progression is impaired; the inability to clear PrP90-231 via autophagy induces cytotoxicity, causing impairment of lysosomal integrity and cytosolic diffusion of hydrolytic enzymes. Conversely, the induction of autophagy by pharmacological blockade of mTOR kinase or trophic factor deprivation restored autophagy resolution, reducing intracellular PrP90-231 accumulation and neuronal death. Taken together, these data indicate that PrP90-231 internalization induces an autophagic defensive response in A1 neurons, although incomplete and insufficient to grant survival; the pharmacological enhancement of this process exerts neuroprotection favoring the clearing of the internalized peptide and could represents a promising neuroprotective tool for neurodegenerative proteinopathies.

Highlights

  • Protein misfolding is the main pathogenic event responsible for synaptic loss, neuronal death, and gliosis during all neurodegenerative disorders[1,2,3,4]

  • In TSE patients, PrP “scrapie” (PrPSc) oligomeric aggregates have been identified in brain areas displaying neuron degeneration, vacuolization, and glial activation[10,11,12], suggesting that during PrPC = > PrPSc transition neurotoxic species are generated before amyloid fibrillogenesis[13,14,15,16]

  • The amount of PrP90-231 (16 KDa 3F4-immunoreactive band) in the lysosomal fraction was significantly reduced after co-treatment with rapamycin (Fig. 6b,c). These results suggest that the activation of autophagy induced by rapamycin significantly reduces the intracellular accumulation of PrP90-231, likely favoring its clearing by autophagy

Read more

Summary

Introduction

Protein misfolding is the main pathogenic event responsible for synaptic loss, neuronal death, and gliosis during all neurodegenerative disorders[1,2,3,4]. Neurotoxicity seems independent from the nature or function of native proteins, but caused by the increased hydrophobicity of oligomers[23,24,25]. In this view, all amyloidogenic polypeptides (PrPSc, Aβ, and α-synuclein) share common neurodegenerative mechanisms[3,26], via oligomers’ interaction with neuronal targets[22,27,28,29], making protein misfolding and aggregation process a valuable target for disease-modifying therapies against neurodegenerative proteinopathies[30]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.